Envisia Therapeutics, Inc. — TTAB Proceedings
Envisia Therapeutics, Inc. is a party to 2 TTAB proceedings.
Proceedings
- Proceeding 91233115 — Oppositions, Terminated (filed 2017-02-27) against Veracyte, Inc. as plaintiff
- Proceeding 86962357 — Extensions of Time to Oppose, Terminated (filed 2016-09-01) against Veracyte, Inc. as plaintiff
Marks in These TTAB Matters
- ENVISIA THERAPEUTICS — proceeding 91233115 (Plaintiff)
Common TTAB Counterparties
- Veracyte, Inc. — 2 proceedings
Recent TTAB Timeline
- 2017-09-11: 91233115 — TERMINATED involving Veracyte, Inc.
- 2017-09-11: 91233115 — BD'S DECISION: DISMISSED W/O PREJUDICE involving Veracyte, Inc.
- 2017-09-01: 91233115 — WITHDRAWAL OF OPPOSITION involving Veracyte, Inc.
- 2017-08-01: 91233115 — SUSPENDED involving Veracyte, Inc.
- 2017-08-01: 91233115 — STIP TO SUSPEND PEND SETTLEMENT NEGOTNS involving Veracyte, Inc.
- 2017-06-01: 91233115 — SUSPENDED involving Veracyte, Inc.
- 2017-06-01: 91233115 — STIP TO SUSPEND PEND SETTLEMENT NEGOTNS involving Veracyte, Inc.
- 2017-03-30: 91233115 — EXTENSION OF TIME GRANTED involving Veracyte, Inc.
- 2017-03-30: 91233115 — STIPULATION FOR AN EXTENSION OF TIME involving Veracyte, Inc.
- 2017-02-27: 91233115 — PENDING, INSTITUTED involving Veracyte, Inc.
- 2017-02-27: 91233115 — NOTICE AND TRIAL DATES SENT; ANSWER DUE: involving Veracyte, Inc.
- 2017-02-27: 91233115 — FILED AND FEE involving Veracyte, Inc.
- 2016-12-21: 86962357 — EXTENSION OF TIME GRANTED involving Veracyte, Inc.
- 2016-12-21: 86962357 — INCOMING - EXT TIME TO OPPOSE FILED involving Veracyte, Inc.
- 2016-12-20: 86962357 — EXTENSION OF TIME GRANTED involving Veracyte, Inc.
- 2016-12-20: 86962357 — INCOMING - EXT TIME TO OPPOSE FILED involving Veracyte, Inc.
- 2016-09-14: 86962357 — EXTENSION OF TIME GRANTED involving Veracyte, Inc.
- 2016-09-14: 86962357 — INCOMING - EXT TIME TO OPPOSE FILED involving Veracyte, Inc.
- 2016-09-01: 86962357 — EXTENSION OF TIME GRANTED involving Veracyte, Inc.
- 2016-09-01: 86962357 — INCOMING - EXT TIME TO OPPOSE FILED involving Veracyte, Inc.